Investigational drug · Phase 2
AZD7798
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Moderate to Severe Crohn's Disease, Crohn's Disease.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
5
Any phase or sponsor naming "AZD7798"
First trial start
2024
Aug 28, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AZD7798", any sponsor or status.
Conditions studied
As listed on its trial records.
- Moderate to Severe Crohn's Disease
- Crohn's Disease
Approved drugs for the same conditions: Crohn's disease · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "AZD7798" as an intervention, largest first.
- Phase IIa Study Evaluating AZD7798 in Crohn's DiseasePivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT06450197 · 120 participants · Start Aug 28, 2024 · Primary completion Apr 30, 2026
Drug: AZD7798 · For: Moderate to Severe Crohn's Disease
Sites: Phoenix, Arizona; Escondido, California; La Jolla, California · 116 sites in all
- AZD7798 Safety, Tolerability, and Pharmacokinetics After a Single Ascending and Repeat Dose Administrations to Healthy Subjects, and Patients With Crohn's DiseasePivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT05452304 · 112 participants · Start Jul 12, 2022 · Primary completion Nov 14, 2024
Drug: AZD7798; Placebo · For: Healthy Subjects; Crohns Disease
Sites: Harrow, United Kingdom
- Study Evaluating AZD7798 for Treatment in Crohn's Disease Patients With an IleostomyActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT06681324 · 24 participants · Start Dec 11, 2024 · Primary completion Aug 10, 2026
Drug: AZD7798 · For: Crohn's Disease
Sites: Leuven, Belgium; Padova, Italy; Roma, Italy · 17 sites in all
AstraZenecaAstraZeneca (AZN)
NCT06053424 · 13 participants · Start Sep 25, 2023 · Primary completion Oct 8, 2024
Drug: AZD7798; [11C]AZ14132516 · For: Crohn's Disease
Sites: Stockholm, Sweden
AstraZenecaAstraZeneca (AZN)
NCT06432764 · 9 participants · Start Oct 16, 2024 · Primary completion Mar 27, 2026
Drug: AZD7798; [11C]AZ14132516 · For: Crohn Disease
Sites: Stockholm, Sweden
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AstraZeneca.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.